Navigation Links
Anaptys Biosciences Appoints R. Scott Greer to Board of Directors
Date:10/8/2007

Former Chairman and CEO of Abgenix Brings Wealth of Industry Experience

LA JOLLA, Calif., Oct. 8 /PRNewswire/ -- Anaptys Biosciences, Inc., a privately-held biopharmaceutical product company, today announced the appointment of R. Scott Greer to the company's board of directors. Mr. Greer, a founder and former chairman and CEO of Abgenix, is a seasoned entrepreneur and executive with more than 20 years of experience in the biopharmaceutical industry.

"Scott Greer is a stellar addition to Anaptys' board," said Tom Smart, chairman and chief executive officer of Anaptys. "Scott's intimate knowledge of the therapeutic antibody space, combined with his impressive talent and track record for building and monetizing successful ventures, will bring invaluable perspective to the Anaptys team as we move toward commercialization of our novel technology and product portfolio."

Mr. Greer is a private investor and active consultant to the life sciences industry. He currently serves as managing director of Numenor Ventures, LLC. In 1996, he founded Abgenix, Inc., a biotechnology company focused on developing and commercializing human antibody based therapeutics, and served as its CEO from inception through 2002 and as its chairman from 2000 until 2006. In 2006, Abgenix was acquired by Amgen, Inc. in a cash transaction worth approximately $2.2 billion.

Mr. Greer also served as chairman of the board of Sirna Therapeutics, Inc. In 2007, Merck acquired Sirna for approximately $1.1 billion in cash.

"Anaptys is raising the bar for antibody-based therapeutics by addressing unsolved problems in protein selection and optimization," said Mr. Greer. "Their technology has true potential to revolutionize the field of therapeutic antibodies. I am excited to contribute to the leadership of this company during this time of significant progress and opportunity."

Prior to forming Abgenix, Mr. Greer spent five years at Cell Genesys, Inc., a biotechnology company, initially as chief financial officer and vice president of corporate development through its early development and initial public offering, and later as senior vice president of corporate development. Prior to Cell Genesys, Greer held various positions at Genetics Institute, Inc. (acquired by American Home Products Inc.), including director of corporate development.

Mr. Greer serves as chairman of Acologix, Inc., a development stage biotech company. He is also an investor in and chairman of Inogen, Inc., a commercial stage medical device company. Greer has held director roles at CV Therapeutics, Inc. Illumina, Inc., and Affymax, Inc., all now publicly traded biotech companies. In 2000, Mr. Greer was honored as Ernst & Young Entrepreneur of the Year (Northern California Life Sciences).

Mr. Greer holds a B.A. in economics from Whitman College and an M.B.A. from Harvard University. Prior to attending business school, Mr. Greer was a certified public accountant and auditor with Coopers & Lybrand.

About Anaptys Biosciences

Anaptys is a privately-held biopharmaceutical product company and the leader in the use of somatic hypermutation (SHM) for antibody discovery and protein optimization. The company's proprietary Omnitope-SHM(TM) System provides a robust platform for evolving and selecting optimized antibodies directed at validated, new, and previously intractable targets. This discovery platform leverages SHM, a natural process for generating antibody diversity, to rapidly and functionally select evolved proteins with enhanced bioactivities. Anaptys is pursuing multiple drug development programs with an initial focus on building a franchise of biologically synergistic product candidates. For more information, visit the company's web site at http://www.anaptysbio.com.


'/>"/>
SOURCE Anaptys Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):